LGND Ligand Pharmaceuticals, Inc. · $303.39 Extended — don't chase; wait for a pullback过度拉升 — 勿追高；等待回撤 Terminal终端 ↗

All coverage所有股票 · Health Care

Ligand Pharmaceuticals, Inc. · Health Care

LGND

$303.39
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas.LigandPharmaceuticals是一家美国生物制药公司，专注于收购和开发产生特许权使用费的资产。截至2024年，公司投资组合涵盖约90种跨治疗领域的药品特许权。
Mixed profile混合特征 Mid cap中盘 $6B
Engine stance引擎立场2026-07-20
Extended — don't chase; wait for a pullback过度拉升 — 勿追高；等待回撤
The bottoming setup is not yet confirmed (price still below the 10-day average) and the 3-day/weekly momentum is rolling筑底形态尚未确认（价格仍位于 10 日均线下方），且3 日/周线动量已开始掉头向下——动量在形态完成前已开始衰竭。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Open in Terminal打开终端 ↗ All coverage所有股票 Data through数据截至 2026-07-20 · regenerated nightly每日更新

Key Statistics关键统计

Price价格
$303.39
6.0% below 52-week high低于52周高点 6.0%
Market Cap市值
$6B
Normal volume正常成交量
P/E Ratio市盈率
48.2x
28.9x sector median
Beta贝塔
0.81
Moves about 0.8x the market波动幅度约为市场的 0.8 倍
RSI (14)RSI（14）
59
Neutral zone中性区域
Next Earnings下次财报
2026-08-06 (18d)
Volatility Rank波动率分位
71th pctile
hist. vol. percentile历史波动率分位数
Short Interest空头兴趣
10.7% of float

Performance价格表现

Period周期 LGND S&P 500vs Index对比指数
1 Week近1周 -4.1% -1.5% Lagged the index by 2.6 points落后指数 2.6 个百分点
1 Month近1月 +15.3% +0.6% Beat the index by 14.7 points跑赢指数 14.7 个百分点
3 Months近3月 +30.9% +4.7% Beat the index by 26.2 points跑赢指数 26.2 个百分点
6 Months近6月 +57.2% +7.8% Beat the index by 49.4 points跑赢指数 49.4 个百分点
Year to date年初至今 +59.6% +9.1% Beat the index by 50.5 points跑赢指数 50.5 个百分点
1 Year近1年 +120.5% +19.4% Beat the index by 101.1 points跑赢指数 101.1 个百分点
3 Years近3年 +345.3% +69.4% Beat the index by 275.9 points跑赢指数 275.9 个百分点

Technicals技术面

RSI (14)RSI（14） 59 Neutral zone中性区域
vs 50-day相对50日均线 +16.5% vs 50-day avg
vs 200-day相对200日均线 +41.5% vs 200-day avg
Volatility rank波动率分位 71th percentile 分位
Engine reference levels — not advice引擎参考水平 — 非投资建议
Buy zone买入区间
$295.90
Don't chase above不追高于
$303.40
Stop止损
$253.20
Extended — wait for a pullback过度拉伸 — 等待回撤

Earnings财务业绩

18
days until next report天后公布财报
2026-08-06

Estimates being cut预期下调

Post-earnings drift: +7.3% (20d)财报后漂移：+7.3%（20日）

Earnings call transcripts — coming soon财报电话会议记录 — 即将上线

Valuation估值

Multiple指标 LGND Sector median行业中位 Cheaper than相对便宜
P/E (trailing)市盈率（历史） 48.20x 28.92
20%
P/B市净率 5.90x 3.52
25%
P/S市销率 22.38x 3.02
3%
Earnings yield盈利收益率 2.07% 2.72
40%
FCF yield自由现金流收益率 0.82% 3.94
17%
Shareholder yield股东收益率 0.25% 1.89
18%
EV/EBITDA企业价值/EBITDA 77.89x 18.21
5%
P/FCF市值/自由现金流 122.67x 22.42
5%
Analyst price targets — coming soon分析师目标价 — 即将上线

Financials财务数据

Revenue营业收入
$186.4M
2020
$277.1M
2021
$196.2M
2022
$131.3M
2023
$167.1M
2024
$268.1M
2025
5yr CAGR5年复合增速: 7.5%
Earnings Per Share每股收益
$-0.18
2020
$3.31
2021
$-1.98
2022
$2.94
2023
$-0.22
2024
$6.13
2025
Free Cash Flow自由现金流
$50.1M
2020
$70.0M
2021
$119.9M
2022
$46.1M
2023
$95.2M
2024
$48.9M
2025
Margins利润率
Operating margin营业利润率
15.3%
Net margin净利率
46.4%
FCF margin自由现金流利润率
18.4%
12.2%Return on Equity股本回报率
8.0%Return on Assets资产回报率
Leverage杠杆
Net debt / EBITDA净债务/EBITDA-2.34
Current ratio流动比率22.23
Capital Allocation资本配置
Stock-based comp股权薪酬$46.8M
Share count change (1y)股数变化（1年）+3.5%
Piotroski皮奥特罗斯基 4/7 Altman Z阿尔特曼Z: safe (8.0) Watch关注

Snapshot Gauges综合指标

Valuation vs Sector估值相对行业
Expensive vs sector相对行业偏贵
Cheaper than 14% of its sector on blended multiples综合估值倍数低于行业内 14% 的公司
Beta市场敏感度
0.81×
0.21×3×
Moves about 0.8× the market波动幅度约为市场的 0.8 倍
Financial Health财务健康
4/7
Altman阿尔特曼: safe
Weak financial health财务健康状况偏弱
Dividend分红
—
Does not pay a dividend不派发股息

Why Is It Moving为何波动

Macro宏观 Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓 Short interest changed +25.6%空头仓位变动 +25.6%
Technical技术面 LGND daily MACD crossed downLGND 日线MACD下穿

Ownership & Smart Money持仓与聪明钱

Insider activity内部人员活动: -$8.5M net (0 buyers, 6 sellers)-$8.5M 净值（0 买家，6 卖家）

Signal History信号历史

NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP. Buyers rejected the 2026-06-15 low (swing low printed) but price hasn't reclaimed its 10-day average — first box ticked, not all买入预备。买方拒绝了 2026-06-15 的低点（摆动低点已现），但价格尚未收复 10 日均线——第一项条件达成，并非全部
TURN SIGNALED BOTTOMING
Jul 13, 2026
LGND daily MACD crossed downLGND 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $309.25.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$309.25。
Jul 9, 2026
LGND made a new 52-week highLGND 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $322.61.价格创出52周新高 — 全市场关注的动量/趋势极值。$322.61。
Jul 2, 2026
LGND made a new 52-week highLGND 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $319.55.价格创出52周新高 — 全市场关注的动量/趋势极值。$319.55。
Jun 23, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jun 23, 2026
LGND made a new 52-week highLGND 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $279.44.价格创出52周新高 — 全市场关注的动量/趋势极值。$279.44。
Jun 23, 2026
LGND RSI reached overboughtLGND RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $279.44.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$279.44。
Jun 22, 2026
NEARING A HIGH → UPTREND接近高点 → 上涨趋势
HOLD持有
Jun 17, 2026
LGND made a new 52-week highLGND 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $263.14.价格创出52周新高 — 全市场关注的动量/趋势极值。$263.14。
Jun 16, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jun 16, 2026
LGND RSI reached overboughtLGND RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $255.25.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$255.25。

Showing last 15 of显示最近15条，共 257 signals条信号

Factor Profile因子特征

Composite factor score综合因子得分: -1.26
Value价值
-0.9
Quality质量
-1.6
Investment资本投入
-3.0
Shareholder payout股东回报
-1.0
Low volatility低波动
+0.1
Low market beta低市场敏感度
+0.0
Earnings quality盈利质量
-1.8
Short interest空头兴趣
+0.0

Company Profile公司档案

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas.LigandPharmaceuticals是一家美国生物制药公司，专注于收购和开发产生特许权使用费的资产。截至2024年，公司投资组合涵盖约90种跨治疗领域的药品特许权。
Get the full picture获取完整视图
Nightly signals, options flow, and factor analysis across all S&P 500 names.每日更新的信号、期权资金流向和因子分析，覆盖所有标普500成分股。
Open Analyzer打开分析器 Browse All Stocks浏览所有股票